Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Moll

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|November 26, 2024
Editorial: Methods in alloimmunity and transplantation: 2023Guido Moll, Andreas Beilhack
Frontiers in Immunology|May 8, 2023
Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysisRaghavan Chinnadurai, Sowmya Viswanathan, Guido Moll
Frontiers in Immunology|April 1, 2024
Editorial: Emerging talents in alloimmunity and transplantation: 2022Guido Moll, Wai H Lim, Olaf Penack
Frontiers in Immunology|July 11, 2022
Editorial: Advances in Heart TransplantationGuido Moll, Zhenhua Dai, Niels Olsen Saraiva Câmara
Frontiers in Immunology|April 4, 2022
Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress SyndromeOlle Ringdén, Guido Moll, Britt Gustafsson, et al.
Frontiers in Immunology|March 6, 2020
Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell TherapiesGuido Moll, Martin J Hoogduijn, James A Ankrum
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 27, 2015
Host-directed therapies for tuberculous pericarditisAlimuddin Zumla, Markus Maeurer, Guido Moll, et al.
Frontiers in Immunology|August 22, 2024
Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experienceOlle Ringdén, Britt-Marie Svahn, Guido Moll, et al.
British Journal of Haematology|February 11, 2020
Editorial comment: variables affecting the presence of mesenchymal stromal cells in the peripheral blood and their relationship with apheresis productGuido Moll, Norman Drzeniek, Julian Kamhieh-Milz, et al.
Stem Cells Translational Medicine|May 31, 2022
Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC ProductsGuido Moll, James A Ankrum, Scott D Olson, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|November 26, 2024
Editorial: Methods in alloimmunity and transplantation: 2023Guido Moll, Andreas Beilhack
Frontiers in Immunology|May 8, 2023
Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysisRaghavan Chinnadurai, Sowmya Viswanathan, Guido Moll
Frontiers in Immunology|April 1, 2024
Editorial: Emerging talents in alloimmunity and transplantation: 2022Guido Moll, Wai H Lim, Olaf Penack
Frontiers in Immunology|July 11, 2022
Editorial: Advances in Heart TransplantationGuido Moll, Zhenhua Dai, Niels Olsen Saraiva Câmara
Frontiers in Immunology|April 4, 2022
Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress SyndromeOlle Ringdén, Guido Moll, Britt Gustafsson, et al.
Frontiers in Immunology|March 6, 2020
Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell TherapiesGuido Moll, Martin J Hoogduijn, James A Ankrum
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 27, 2015
Host-directed therapies for tuberculous pericarditisAlimuddin Zumla, Markus Maeurer, Guido Moll, et al.
Frontiers in Immunology|August 22, 2024
Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experienceOlle Ringdén, Britt-Marie Svahn, Guido Moll, et al.
British Journal of Haematology|February 11, 2020
Editorial comment: variables affecting the presence of mesenchymal stromal cells in the peripheral blood and their relationship with apheresis productGuido Moll, Norman Drzeniek, Julian Kamhieh-Milz, et al.
Stem Cells Translational Medicine|May 31, 2022
Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC ProductsGuido Moll, James A Ankrum, Scott D Olson, et al.
Pageof 7